Innovita Biological Technology Co., Ltd. (SHA:688253)
China · Delayed Price · Currency is CNY 56.03
+0.21 (0.38%)
At close: Aug 4, 2026
SHA:688253 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 323.87 | 422.03 | 621.39 | 478.02 | 446.62 | 326.91 | |
Revenue Growth | -40.76% | -32.08% | 29.99% | 7.03% | 36.62% | -68.48% |
Cost of Revenue | 86.87 | 96.09 | 127.53 | 140.51 | 173.94 | 77.24 |
Gross Profit | 237 | 325.94 | 493.86 | 337.51 | 272.67 | 249.67 |
Selling, General & Admin | 97.76 | 104.49 | 149.62 | 99.11 | 90.84 | 83.96 |
Research & Development | 78.42 | 94.91 | 97.17 | 53.11 | 72.18 | 31.11 |
Other Operating Expenses | 2.25 | 3.3 | 3.01 | 1.44 | 8.89 | 2.87 |
Operating Expenses | 168.62 | 195.46 | 253.83 | 158.57 | 178.08 | 117.58 |
Operating Income | 68.39 | 130.49 | 240.03 | 178.94 | 94.59 | 132.09 |
Interest Expense | -0.19 | -0.16 | -0.11 | -0.2 | -0.41 | -0.13 |
Interest & Investment Income | 19.68 | 23.6 | 30.74 | 24.57 | 12.11 | 3.59 |
Currency Exchange Gain (Loss) | -1.2 | -1.2 | 1.14 | 0.57 | 42.65 | -9.76 |
Other Non Operating Income (Expenses) | -0.88 | -0.24 | -3.92 | 0.34 | -0.6 | -0.11 |
EBT Excluding Unusual Items | 85.8 | 152.49 | 267.87 | 204.22 | 148.35 | 125.68 |
Gain (Loss) on Sale of Investments | 8.61 | 8.02 | 7.46 | 9.15 | 2.23 | 0.89 |
Gain (Loss) on Sale of Assets | -0.02 | -0.02 | -0.1 | -0.01 | 0.01 | - |
Asset Writedown | -1.8 | -2.19 | - | -19.54 | - | -0 |
Other Unusual Items | 1.36 | 1.36 | 1.29 | 4.54 | 13.92 | 11.24 |
Pretax Income | 93.94 | 159.66 | 276.53 | 198.36 | 164.51 | 137.81 |
Income Tax Expense | 4.13 | 15.19 | 29.67 | 24.41 | 13.82 | 17.65 |
Earnings From Continuing Operations | 89.82 | 144.47 | 246.86 | 173.95 | 150.68 | 120.16 |
Minority Interest in Earnings | - | - | - | - | - | 0.09 |
Net Income | 89.82 | 144.47 | 246.86 | 173.95 | 150.68 | 120.25 |
Net Income to Common | 89.82 | 144.47 | 246.86 | 173.95 | 150.68 | 120.25 |
Net Income Growth | -54.19% | -41.48% | 41.92% | 15.44% | 25.31% | -78.96% |
Shares Outstanding (Basic) | 136 | 136 | 136 | 136 | 122 | 102 |
Shares Outstanding (Diluted) | 136 | 136 | 136 | 136 | 122 | 102 |
Shares Change | -0.12% | -0.07% | 0.36% | 11.83% | 19.24% | 2.90% |
EPS (Basic) | 0.66 | 1.06 | 1.81 | 1.28 | 1.24 | 1.18 |
EPS (Diluted) | 0.66 | 1.06 | 1.81 | 1.28 | 1.24 | 1.18 |
EPS Growth | -54.14% | -41.44% | 41.41% | 3.23% | 5.08% | -79.55% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 23.82 | 162 | 269.31 | 242.89 | 68.71 | 42.52 |
Free Cash Flow Per Share | 0.17 | 1.19 | 1.98 | 1.79 | 0.56 | 0.42 |
Dividend Per Share | 0.450 | 0.450 | 0.560 | 0.400 | 0.166 | - |
Dividend Growth | -19.64% | -19.64% | 40.00% | 140.96% | - | - |
Gross Margin | 73.18% | 77.23% | 79.48% | 70.60% | 61.05% | 76.37% |
Operating Margin | 21.12% | 30.92% | 38.63% | 37.43% | 21.18% | 40.41% |
Profit Margin | 27.73% | 34.23% | 39.73% | 36.39% | 33.74% | 36.79% |
Free Cash Flow Margin | 7.36% | 38.39% | 43.34% | 50.81% | 15.38% | 13.01% |
EBITDA | 91.9 | 153.05 | 258.8 | 200.92 | 111.08 | 145.29 |
EBITDA Margin | 28.38% | 36.27% | 41.65% | 42.03% | 24.87% | 44.45% |
D&A For EBITDA | 23.51 | 22.56 | 18.77 | 21.98 | 16.49 | 13.21 |
EBIT | 68.39 | 130.49 | 240.03 | 178.94 | 94.59 | 132.09 |
EBIT Margin | 21.12% | 30.92% | 38.63% | 37.43% | 21.18% | 40.41% |
Effective Tax Rate | 4.40% | 9.51% | 10.73% | 12.31% | 8.40% | 12.80% |
Revenue as Reported | 323.87 | 422.03 | 621.39 | 478.02 | 446.62 | 326.91 |